Cargando…

Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study

BACKGROUND: The occurrence of KRAS mutations and their association with prognosis in metastatic colorectal cancer patients is not well documented in population-based studies. OBJECTIVES: To examine the feasibility of identifying archived colorectal cancer specimens, and through linkage with nationwi...

Descripción completa

Detalles Bibliográficos
Autores principales: Montomoli, Jonathan, Hamilton-Dutoit, Stephen Jacques, Frøslev, Trine, Taylor, Aliki, Erichsen, Rune
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449754/
https://www.ncbi.nlm.nih.gov/pubmed/23028236
http://dx.doi.org/10.2147/CEG.S34725
_version_ 1782244352096993280
author Montomoli, Jonathan
Hamilton-Dutoit, Stephen Jacques
Frøslev, Trine
Taylor, Aliki
Erichsen, Rune
author_facet Montomoli, Jonathan
Hamilton-Dutoit, Stephen Jacques
Frøslev, Trine
Taylor, Aliki
Erichsen, Rune
author_sort Montomoli, Jonathan
collection PubMed
description BACKGROUND: The occurrence of KRAS mutations and their association with prognosis in metastatic colorectal cancer patients is not well documented in population-based studies. OBJECTIVES: To examine the feasibility of identifying archived colorectal cancer specimens, and through linkage with nationwide Danish population-based databases to investigate the prevalence of KRAS mutations and their association with colorectal cancer survival. METHODS: We used the Danish Pathology Database to identify the physical location of primary (or in some cases secondary) tumor specimens from selected metastatic colorectal cancer patients referred to our hospital for palliative chemotherapy between November 1, 2008 and September 30, 2009. Routinely stored paraffin tissue blocks were obtained from the pathology archives of the originating hospital. KRAS mutation tumor status was assessed for each patient using the commercialized TheraScreen KRAS Mutation Kit. Using the unique identifier number, we linked the patients to the Danish National Registry of Patients and the Danish Civil Registration System to obtain data on date of first colorectal cancer diagnosis and follow-up status. We estimated prevalence of KRAS mutations and the 1-, 2-, and 5-year survival after colorectal cancer diagnosis using the Kaplan–Meier technique. RESULTS: We identified 106 metastatic colorectal cancer patients (64% males). All were successfully linked to the registries, and archived tumor-tissue samples were obtained and analyzed in each case. The overall prevalence of KRAS mutations was 55%, and 1-, 2-, and 5-year overall survival after colorectal cancer diagnosis was 91%, 68%, and 25%, respectively. CONCLUSION: It is feasible to use Danish population-based registries to obtain archived tissue samples from metastatic colorectal cancer patients, and to estimate prevalence of KRAS mutation and subsequently evaluate the association with colorectal cancer survival.
format Online
Article
Text
id pubmed-3449754
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34497542012-10-01 Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study Montomoli, Jonathan Hamilton-Dutoit, Stephen Jacques Frøslev, Trine Taylor, Aliki Erichsen, Rune Clin Exp Gastroenterol Original Research BACKGROUND: The occurrence of KRAS mutations and their association with prognosis in metastatic colorectal cancer patients is not well documented in population-based studies. OBJECTIVES: To examine the feasibility of identifying archived colorectal cancer specimens, and through linkage with nationwide Danish population-based databases to investigate the prevalence of KRAS mutations and their association with colorectal cancer survival. METHODS: We used the Danish Pathology Database to identify the physical location of primary (or in some cases secondary) tumor specimens from selected metastatic colorectal cancer patients referred to our hospital for palliative chemotherapy between November 1, 2008 and September 30, 2009. Routinely stored paraffin tissue blocks were obtained from the pathology archives of the originating hospital. KRAS mutation tumor status was assessed for each patient using the commercialized TheraScreen KRAS Mutation Kit. Using the unique identifier number, we linked the patients to the Danish National Registry of Patients and the Danish Civil Registration System to obtain data on date of first colorectal cancer diagnosis and follow-up status. We estimated prevalence of KRAS mutations and the 1-, 2-, and 5-year survival after colorectal cancer diagnosis using the Kaplan–Meier technique. RESULTS: We identified 106 metastatic colorectal cancer patients (64% males). All were successfully linked to the registries, and archived tumor-tissue samples were obtained and analyzed in each case. The overall prevalence of KRAS mutations was 55%, and 1-, 2-, and 5-year overall survival after colorectal cancer diagnosis was 91%, 68%, and 25%, respectively. CONCLUSION: It is feasible to use Danish population-based registries to obtain archived tissue samples from metastatic colorectal cancer patients, and to estimate prevalence of KRAS mutation and subsequently evaluate the association with colorectal cancer survival. Dove Medical Press 2012-09-18 /pmc/articles/PMC3449754/ /pubmed/23028236 http://dx.doi.org/10.2147/CEG.S34725 Text en © 2012 Montomoli et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Montomoli, Jonathan
Hamilton-Dutoit, Stephen Jacques
Frøslev, Trine
Taylor, Aliki
Erichsen, Rune
Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title_full Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title_fullStr Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title_full_unstemmed Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title_short Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
title_sort retrospective analysis of kras status in metastatic colorectal cancer patients: a single-center feasibility study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449754/
https://www.ncbi.nlm.nih.gov/pubmed/23028236
http://dx.doi.org/10.2147/CEG.S34725
work_keys_str_mv AT montomolijonathan retrospectiveanalysisofkrasstatusinmetastaticcolorectalcancerpatientsasinglecenterfeasibilitystudy
AT hamiltondutoitstephenjacques retrospectiveanalysisofkrasstatusinmetastaticcolorectalcancerpatientsasinglecenterfeasibilitystudy
AT frøslevtrine retrospectiveanalysisofkrasstatusinmetastaticcolorectalcancerpatientsasinglecenterfeasibilitystudy
AT tayloraliki retrospectiveanalysisofkrasstatusinmetastaticcolorectalcancerpatientsasinglecenterfeasibilitystudy
AT erichsenrune retrospectiveanalysisofkrasstatusinmetastaticcolorectalcancerpatientsasinglecenterfeasibilitystudy